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To evaluate the influence of an active inflammatory process in the liver on Gd-EOB-DTPA-
enhanced MR imaging in patients with different degrees of fibrosis/cirrhosis.
Material and methods
Overall, a number of 91 patients (61 men and 30 women; mean age 58 years) were included
in this retrospective study. The inclusion criteria for this study were Gd-EOB-DTPA-
enhanced MRI of the liver and histopathological evaluation of fibrotic and inflammatory
changes. T1-weighted VIBE sequences of the liver with fat suppression were evaluated to
determine the relative signal change (RE) between native and hepatobiliary phase (20min).
In simple and multiple linear regression analyses, the influence of liver fibrosis/cirrhosis
(Ishak score) and the histopathological degree of hepatitis (Modified Hepatic Activity Index,
mHAI) on RE were evaluated.
Results
RE decreased significantly with increasing liver fibrosis/cirrhosis (p < 0.001) and inflamma-
tion (mHAI, p = 0.004). In particular, a correlation between RE and periportal or periseptal
boundary zone hepatitis (moth feeding necrosis, mHAI A, p = 0.001) and portal inflammation
(mHAI D, p < 0.001) was observed. In multiple linear regression analysis, both the degree of
inflammation and the degree of fibrosis were significant predictors for RE (p < 0.01).
Conclusion
The results of this study suggest that the MR-based hepatic enhancement index RE is not
only influenced by the degree of fibrosis, but also by the degree of inflammation.
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Introduction
Inflammation is an immune-mediated reaction to infections and foreign bodies. It can be dis-
tinguished into acute and chronic inflammation, which differ in duration, onset, and outcome.
While acute inflammation can be treated reversibly, recurrent acute inflammation due to per-
sistent acute infection may lead to tissue injury and destruction. Thereof, fibrosis results as a
consequence of the pathophysiological response following tissue injury. However, the distinc-
tion between physiology and pathology is blurry as the right degree of inflammation and repair
can heal a wound and restore tissue integrity and function, whereas excessive, uncontrolled
inflammation or repair mechanisms may lead to tissue dysfunction. Inflammation may induce
hepatocellular damage which will activate and promote hepatic stellate cells and Kupffer cells
and finally leads to an inflammatory and fibrogenic response [1–3]. Consequently, the
enhanced inflammatory and immune-mediated responses will promote additional hepatocyte
necrosis and apoptosis, which triggers further fibrogenic processes [4]. By intervening in the
signaling pathways that influence myofibroblast apoptosis, hepatic stellate cell inactivation,
and extracellular matrix degeneration, hepatic fibrosis can be prevented or even reversed, it is
therefore important to recognise inflammatory processes as early as possible in order to be
able to take appropriate countermeasures.
Liver biopsy is the current gold standard for the diagnosis and evaluation of liver fibrosis, cir-
rhosis and inflammation in clinical practice. However liver biopsies are invasive procedures. They
have poor patient compliance, are prone to sampling errors, and variability between observers.
Moreover, they are associated with risks of complications such as infection and bleeding [5]. The
absence of characteristic fibrotic septa and nodular configurations may impede histological diag-
nosis [6]. In addition, sampling errors may underestimate the severity of the disease [7, 8].
Heterogeneous hepatic parenchyma diseases may interfere with global liver function tests,
e.g. the ICG-Test, as these tests cannot detect regional defects or hepatic compensation of
them. Furthermore, an assessment of liver parenchyma using a dynamic imaging technique,
such as ultrasound, is limited in terms of reproducibility [9]. Predictions on liver parenchyma
may benefit from image-based tests for detecting regional and global liver changes. In recent
years, liver-specific Gd-EOB-DTPA-enhanced MRI has evolved as a promising tool to assess
liver function or stage liver fibrosis [10, 11].
In this study, the relationship between histopathological findings and the hepatic enhance-
ment on Gd-EOB-DTPA-enhanced MRI were investigated to evaluate the effect of the hepatic
inflammation status on contrast-enhanced signal intensity indices.
Materials and methods
Patients
A retrospective subgroup analysis was performed on a reported dataset over the correlation
between liver fibrosis and Gd-EOB-DTPA-enhanced MRI, published October 2015 in Scien-
tific Reports [12], Fig 1.
Approval from the local institutional review board of the University Hospital Regensburg
was obtained, and this retrospective study was performed following the relevant guidelines
and regulations. Written informed consent was obtained from all subjects.
Overall, 91 patients (61 men and 30 women; mean age, 58 years) were included in this ret-
rospective study. The criteria for inclusion in this study were Gd-EOB-DTPA-enhanced MRI
of the liver as well as evaluation of histopathological liver samples concerning fibrotic and
inflammation findings (within three months of the examination). Detailed patient characteris-
tics are given in Table 1.
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n = 139 (02/2012 - 10/2014);
patients undergone Gd-EOB-DTPA-enhanced MR imaging of the liver 
and provided histopathological liver samples within three months of 
the examination
n = 56; 
tissue lengths shorter than 15mm and/or less 
than ten visible portal tracts
n =18; sampling errors
n=56; 
incompled MR imaging protocol, presence of 
severe imaging artifacts due to surgical clips or 
poor breath-holding techniques
n = 98;
Liver fibrosis and Gd-EOB-DTPA-enhanced MRI: A 
histopathologic correlation. Scientific reports. 2015;5:15408. 
doi: 10.1038/srep15408.
n = 7; 
missing information regarding the degree of 
hepatic inflammation 
n = 91;
Influence of hepatic fibrosis and inflammation on Gd-EOB-
DTPA-enhanced MR Imaging
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MR imaging
All imaging was performed using a clinical whole-body 3-T system (MAGNETOM Skyra, Sie-
mens Healthcare, Erlangen, Germany) with an 18-channel body matrix coil and a 32-channel
spine matrix coil for signal perception. T1-weighted VIBE sequences with fat suppression and
following MR settings were applied: repetition time (TR), 3.09 ms; echo time (TE), 1.17 ms;
flip angle, 10˚; parallel imaging factor, 2; slices, 64; reconstructed voxel size, 1.25 x 1.25 x 3.0
mm3; measured voxel size, 1.71 x 1.25 x 4.5 mm3; acquisition time, 14 sec. Images were
acquired during breath-holding before, and 20 min after Gd-EOB-DTPA (Primovist1, Bayer
Healthcare, Berlin) administration and every sequence covered the entire liver in the plain and
the hepatobiliary phase (HBP).
The i.v.-injected Gd-EOB-DTPA dose was body weight adapted (0.025 mmol/kg body
weight) and administered via bolus injection (flow rate, 1 mL/s), followed by 0.9% sodium
chloride (20 mL).
Image analysis
Signal intensity (SI) values were obtained by operator-defined region-of-interest (ROI) mea-
surements of the liver (left liver lobe, 3 ROIs; right liver lobe, 3 ROIs) in T1-weighted VIBE
images (before and after Gd-EOB-DTPA injection). The ROIs (circle shape, 1.0 cm2 - 3.5 cm2)
Fig 1. Flowchart of patient inclusion. The criteria for inclusion in this study were Gd-EOB-DTPA-enhanced MRI of the liver as well as evaluation of
histopathological liver samples concerning fibrotic and inflammation findings (within three months of the examination) from a patient cohort
analyzed in 2015.
https://doi.org/10.1371/journal.pone.0215752.g001
Table 1. Baseline characteristics of the included patient cohort.
parameters n = 91 (n = 65, liver resections; n = 35, needle biopsies)
male 61 (67.0%)
age [years] 58.21 ± 13.66
height [m] 1.72 ± 0.09
weight [kg] 81.2 ± 16.33
BMI [kg/m2] 27.17 ± 4.72
modified HAI 2.70 ± 2.19
Ishak-Score 2.27 ± 2.12
Hepatocellular carcinoma 24 (26.4%)
Cholangiocellular carcinoma 10 (11.0%)
liver metastasis 20 (22.0%)
benign hepatic lesion 6 (6.6%)
Virus hepatitis 20 (22.0%)
Alcoholic liver disease 17 (18.7%)
biliary disease 9 (9.9%)
Nonalcoholic fatty liver disease 7 (7.7%)
Non-alcoholic steatohepatitis 3 (3.3%)
Autoimmune hepatitis 1 (1.1%)
Cardiac cirrhosis 1 (1.5%)
The data are presented as mean (M) ± standard deviation (SD).
BMI: body-mass-index as a function of body weight to body height; Modified HAI: modified histologic activity
index, based on findings of inflammation according to Ishak [14]; Ishak-Score: Histologic fibrosis index, based on
fibrotic findings according to Ishak [14].
https://doi.org/10.1371/journal.pone.0215752.t001
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were manually placed at identical locations in every sequence while excluding liver lesions,
major branches of the portal and hepatic veins and imaging artifacts.
The following formula was applied to evaluate the liver function based on SI-values:




The results of the histopathological samples were included if the report included fibrotic and
inflammatory findings. All samples were fixed in formalin and embedded in paraffin for verti-
cal microcuts (4 μm thickness). The cuts were mounted on glass slides, deparaffined with
xylene and ethanol and stained with hematoxylin-eosin (HE) and Elastica van Gieson (EVG)
according to standard protocols. Based on the specific staining (collagen, red; hepatocytes, yel-
low), the EVG was used to assess liver fibrosis. The samples were evaluated by two pathologists
with professional expertise in liver histopathology. The readers scored independently of each
other, while they were blinded for MR image analysis and patient data. In variation assess-
ments, additional microscopic investigations were carried out jointly. Fibrosis and degree of
inflammation were classified according to the Ishak Scoring System [13, 14].
Statistical analysis
Simple linear regression models were used to determine the predictive power of SI-based indi-
ces in comparison to histopathological findings. Furthermore, a multiple linear regression
model including Ishak Score and mHAI was calculated to investigate the additional variance
elucidation of mHAI for the whole patient groups and based on parenchymal and tumorous
diseases. Regression coefficients (B) with corresponding 95%-confidence intervals (95% CI)
and the coefficient of determination (R2) are reported as effect estimates. The statistical signifi-
cance level was set to 0.05 (two-sided), and all analyses were performed using SPSS software
(version 24; IBM, Chicago, IL, USA).
Results
Histopathological findings
Eleven Patients showed no sign of hepatic fibrosis or inflammation. Six Patients presented a
hepatic inflammation without an underlying fibrotic or cirrhotic liver parenchyma. Liver fibrosis/
cirrhosis without hepatic inflammation occurred in eleven patients. Sixty-three patients showed
an active inflammation in their liver fibrosis/cirrhosis (Table 2). The level of inflammation showed
a significant correlation with the level of fibrosis/cirrhosis (p = 0.013, r = 0.260; Fig 2).
In the case of liver fibrosis classification, 18.7% of the examined samples were free of fibro-
sis, while 62.6% showed different stages of fibrosis, and 18.7% had characteristics of cirrhosis
(Table 3).
Table 2. Hepatic fibrosis in correlation to hepatic inflammation.
hepatic inflammation
mHAI = 0 mHAI � 1
hepatic fibrosis Ishak-Score = 0 11 (64.7) 6 (35.3)
Ishak-Score � 1 11 (14.9) 63 (85.1)
The modified histologic activity index (mHAI) and the Ishak-Score as histologic fibrosis index based on Ishak [14]
were used to evaluate the liver parenchyma. Data is presented as n with the percentage value within hepatic fibrosis.
https://doi.org/10.1371/journal.pone.0215752.t002
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During hepatic inflammation different histopathological characteristics could be found,
which should be analyzed separately. The sum of all criteria-points (A to D) then represents
than the modified HAI (mHAI). In 73.6% of patient cases evaluated for mHAI A, no periportal
or periseptal interface hepatitis was observed in the examined liver tissue samples. Only one
samples showed a confluent necrosis (mHAI B), and 53.8% showed no sign of focal lytic necro-
sis, apoptosis and focal inflammation (mHAI C). Different stages of portal inflammation
(mHAI D) could be observed in 65.9% of the examined samples (Table 4).
In Fig 3 representative images for normal hepatic tissue without the presence of a fibrotic and
inflammatory process (Fig 3A) and fibrotic hepatic tissue with inflammation (Fig 3B) are shown
in addition to corresponding MR images. An increase of collagen tissue can be observed easily.
Comparison of MRI-based hepatic enhancement indices to modified
Histology Activity Index
Visual examination of the scatterplots revealed a linear relationship between mHAI and the
MRI-based hepatic enhancement index relative enhancement (RE) (Fig 4A). Simple linear
Fig 2. The level of inflammation plotted against the level of fibrosis/cirrhosis. The figure shows the level of inflammation, as characterized by the histologic activity
index (mHAI) in comparison to the Ishak-Score. A dash indicates the mean of each group in the data cloud.
https://doi.org/10.1371/journal.pone.0215752.g002
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regression analyses (Table 5) showed significant correlations of mHAI to the tested MRI-based
hepatic enhancement indices RE (r2 = 0.142; p =< 0.001), SIHBP (r
2 = 0.166; p =< 0.001) and
SInativ (r
2 = 0.072; p = 0.010).
In a subgroup analysis regarding the influence of the tissue sample we found no significant
correlation of mHAI to the tested MRI-based hepatic enhancement index RE for needle biop-
sies whereas significant correlations could be observed for liver resections. In these subgroups
Table 3. Ishak-Score as histologic fibrosis index based on Ishak [14].
Ishak-Score points n RE SI(HBP) SI(plain)
no fibrosis 0 17 1.13 ± 0.18 421.10 ± 71.21 199.15 ± 39.10
Fibrosis expansion of some portal areas, with or without short fibrous septa 1 18 0.89 ± 0.15 336.59 ± 60.57 177.86 ± 27.46
Fibrous expansion of most portal areas, with or without short fibrous septa 2 17 0.79 ± 0.17 313.64 ± 44.58 174.56 ± 26.46
Fibrous expansion of most portal areas with occasional portal to portal bridging 3 5 0.70 ± 0.10 292.60 ± 68.35 170.45 ± 30.70
Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central) 4 8 0.56 ± 0.21 266.23 ± 53.24 169.13 ± 24.15
Marked bridging (portal-portal and/or portal-central) with occasional nodules (incomplete cirrhosis) 5 9 0.37 ± 0.14 257.34 ± 70.20 184.96 ± 34.67
Cirrhosis, probable or definite 6 17 0.26 ± 0.11 211.72 ± 51.77 166.50 ± 32.62
The data are presented as mean ± standard deviation (SD). Scoring system is based on histopathologic findings of collagen and hepatocytes. RE: relative enhancement as
a function of SI-based indices of the hepatic parenchyma. SI: hepatic signal enhancement in plain or hepatobiliary (HBP) phase.
https://doi.org/10.1371/journal.pone.0215752.t003
Table 4. Modified histologic activity index (mHAI) based on Ishak [14].
points n RE SI(HBP) SI(plain)
mHAI A: Periportal or periseptal interface hepatitis
(piecemeal necrosis)
None 0 67 0.80 ± 0.32 331.70 ± 83.34 184.75 ±31.97
Mild (focal, few portal areas) 1 17 0.45 ± 0.27 245.07 ± 74.01 166.87 ± 33.612
Mild / moderate (focal, most areas) 2 6 0.44 ± 0.23 221.97 ± 76.05 152.11 ± 31.77
Moderate (continuous around < 50% of
tracts or septa)
3 0 - - -
Severe (continuous around
> 50% of tracts or septa)
4 1 0.73 301.00 173.83
mHAI B: Confluent necrosis None 0 90 0.71 ± 0.34 307.53 ± 90.13 178.43 ± 32.50
Focal confluent necrosis 1 0 - - -
Zone 3 necrosis in some areas 2 0 - - -
Zone 3 necrosis in most areas 3 0 - - -
Zone 3 necrosis + occasional portal-central
bridging
4 0 - - -
Zone 3 necrosis + multiple portal-central
bridging
5 0 - - -
Panacinar or multiacinar necrosis 6 1 0.76 345.33 196.17
mHAI C: Focal (spotty) lytic necrosis, apoptosis and focal
inflammation
None 0 49 0.76 ± 0.34 324.62 ± 87.60 184.17 ± 32.82
One focus or less per 10x objective 1 24 0.62 ± 0.33 288.81 ± 91.71 176.01 ± 32.82
Two to four foci per 10x objective 2 15 0.73 ± 0.36 291.57 ± 91.72 167.14 ± 29.52
Five to ten foci per 10x objective 3 1 0.30 175.80 135.23
More than 10 foci per 10x objective 4 2 0.76 ± 0.03 318.12 ± 24.20 181.08 ± 10.25
mHAI D: Portal inflammation None 0 31 0.91 ± 0.31 364.82 ± 90.36 190.08 ± 32.72
Mild, some or all portal areas 1 27 0.76 ± 0.30 309.00 ± 65.30 176.28 ± 27.89
Moderate, some or all portal areas 2 28 0.48 ± 0.26 250.01 ± 74.47 167.34 ± 33.39
Moderate/marked, all portal areas 3 5 0.48 ± 0.20 274.18 ± 68.52 183.43 ± 31.56
Marked, all portal areas 4 0 - - -
The data are presented as mean ± standard deviation (SD). Sum of all criteria-points represents the modified HAI. RE: relative enhancement as a function of SI-based
indices of the hepatic parenchyma. SI: hepatic signal enhancement in plain or hepatobiliary (HBP) phase.
https://doi.org/10.1371/journal.pone.0215752.t004
Influence of hepatic fibrosis and inflammation on Gd-EOB-DTPA-enhanced MR imaging
PLOS ONE | https://doi.org/10.1371/journal.pone.0215752 May 13, 2019 7 / 16
AB
Fig 3. Representative images of a case with (A) high hepatic enhancement (RE: 1.29), absent inflammation (mHAI 0) and no fibrotic marker (ISHAK 0) is shown in
comparison to a case with (B) low hepatic enhancement (RE: 0.30) paired with active inflammation (mHAI 9) and fibrosis (ISHAK 4). The first column represents the
non-contrasted MR image while the second column represents the hepatobiliary phase. The corresponding histopathological imaging of the evaluated hepatic sections is
shown in the third column. All displayed MR images have the same window and center level. The scale bar on histopathological images represents 500 μm.
https://doi.org/10.1371/journal.pone.0215752.g003
Fig 4. Relative enhancement (RE) values plotted with corresponding mHAI (A) and Ishak-Score (B) separately and combined (C). A dash indicates the mean of each
group in the data cloud. Each dot represents the median of the combined model in graph C. The corresponding correlations with RE as the dependent variable are as
followed: mHAI, r2 = 0.142, p =< 0.001; Ishak-Score, r2 = 0.792, p< 0.001. The combined model accounts for an R2 of 0.815.
https://doi.org/10.1371/journal.pone.0215752.g004
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the coefficient of determination (r2) increased for each tested value: RE, r2 = 0.267, p =<
0.001; SIHBP, r
2 = 0.253, p = 0.001; SInativ, r
2 = 0.100, p = 0.018 (Table 5).
Regarding the subgroups of the overall mHAI the best coefficient of determination values
was observed for mHAI D (portal inflammation) in relation to RE (r2 = 0.278; p< 0.001) and
SIHBP (r
2 = 0.244; p< 0.001; Table 6). A subgroup analysis of the investigated tissue was not
possible due to the small sample size.
Comparison of MRI-based hepatic enhancement indices to Ishak-Score
The scatterplot revealed a stringent linear relationship between the MRI-based hepatic
enhancement index RE and the Ishak-Score (Fig 4B). The linear regression models of fibrotic
markers on the signal intensity-based indices showed high coefficients of determination with
significant character for RE (r2 = 0.792; p< 0.001) and SIHBP (r
2 = 0.543; p< 0.001; Table 5).
In contrast to the results of the subgroup analysis of the comparison of MRI-based hepatic
enhancement indices to modified Histology Activity Index the coefficient of determination
decreased in case of liver resection for RE, r2 = 0.768, p = 0.010 and SIHBP, r
2 = 0.528, p< 0.001.
No significant correlation could be observed regarding the influence on SInativ for needle biopsies
(p = 0.160), while still a significant correlation for liver resection (p = 0.011) was observed.
Multiple linear regression analysis of MRI-based hepatic enhancement
indices to histopathological findings
In a multiple linear regression analysis, the effect of the Ishak-Score and mHAI were tested
towards RE (Table 7). Both independent variables showed to be significant predictors of RE
values (R2 = 0.815; Table 7, Fig 4C).
Table 5. Simple linear regression models of SI-based indices with HFI and modified HAI.
B (95% CI) r2 p-value
RE Ishak-Score - 0.14 (- 0.15; - 0.12) 0.792 < 0.001
liver resection - 0.13 (- 0.15; - 0.11) 0.768 0.010
needle biopsy - 0.15 (- 0.17; - 0.12) 0.818 0.012
mHAI - 0.06 (- 0.09; - 0.02) 0.142 < 0.001
liver resection - 0.09 (- 0.13; - 0.05) 0.267 < 0.001
needle biopsy - 0.04 (- 0.09; - 0.01) 0.086 0.087
SIHBP Ishak-Score - 30.20 (- 36.04; - 24.36) 0.543 < 0.001
liver resection - 32.38 (- 40.74; - 24.02) 0.528 < 0.001
needle biopsy - 27.65 (- 36.22; - 19.01) 0.566 < 0.001
mHAI - 17.27 (- 25.41; - 9.12) 0.166 < 0.001
liver resection - 25.69 (- 37.72; - 13.66) 0.253 0.001
needle biopsy - 11.79 (- 23.27; - 0.31) 0.117 0.044
SIplain Ishak-Score - 3.55 (- 6.58; - 0.53) 0.058 0.022
liver resection - 5.50 (- 9.67; - 1.34) 0.115 0.011
needle biopsy - 1.63 (- 6.27; 3.01) 0.015 0.479
mHAI - 4.11 (- 7.21; - 1.01) 0.072 0.010
liver resection - 5.85 (- 10.66; - 1.03) 0.100 0.018
needle biopsy - 2.81 (- 7.08; - 1.47) 0.051 0.190
RE: relative enhancement as a function of SI-based indices of the hepatic parenchyma. SI: hepatic signal
enhancement in plain or hepatobiliary (HBP) phase. mHAI: modified histologic activity index, based on findings of
inflammation according to Ishak [14]: Ishak-Score: Histologic fibrosis index, based on fibrotic findings according to
Ishak [14]. r2: coefficient of determination. p-value: level of significance.
https://doi.org/10.1371/journal.pone.0215752.t005
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Influence of hepatic inflammation (mHAI) on parenchymal enhancement
for patients with known parenchymal and tumor diseases
In a multiple linear regression analysis, the effect of the Ishak-Score and mHAI were tested
towards RE in patients who with unknown/non-parenchymal disease, known inflammatory-,
and non-inflammatory-parenchymal disease (Table 8, Fig 5). For patients with unknown/non-
parenchymal disease (Fig 5A, R2 = 0.503) the dominant factor was the liver fibrosis score
(p� 0.001), while the inflammatory showed no additional significant further variance elucida-
tion (p = 0.319). The mHAI remained a significant influence factor in patients with known
inflammatory-parenchymal disease (Fig 5B, p = 0.022, R2 = 0.849), as well as in patients with
non-inflammatory-parenchymal disease (Fig 5C, p = 0.027, R2 = 0.812).
The multiple linear regression analysis reviled that mHAI remained a significant influence
factor in patients with non-tumorous (Fig 6A, p = 0.015) and malignant tumorous diseases
(Fig 6C, p = 0.015) with a higher R2 in patients with non-tumorous (R2 = 0.852) compared to
malignant tumorous diseases (R2 = 0.751). In patients with benign tumorous diseases (Fig 6B)
no significant correlation was observed.
Table 6. Simple linear regression models of SI-based indices with modified HAI and specific criteria of modified
HAI (mHAI).
B (95% CI) r2 p-value
RE mHAI - 0.06 (- 0.09; - 0.02) 0.142 < 0.001
mHAI A - 0.17 (- 0.26; - 0.07) 0.123 0.001
mHAI B - 0.01 (- 0.10; 0.12) 0.000 0.785
mHAI C - 0.03 (- 0.10; 0.05) 0.007 0.419
mHAI D - 0.19 (- 0.26; -0.13) 0.278 < 0.001
SIHBP mHAI - 17.27 (- 25.41; - 9.12) 0.166 < 0.001
mHAI A - 47.26 (- 72.05; - 22.47) 0.139 < 0.001
mHAI B 6.30 (- 23.71; 36.31) 0.002 0.678
mHAI C - 16.11 (- 36.05; 3.83) 0.028 0.017
mHAI D - 47.45 (- 65.05; - 29.85) 0.244 < 0.001
SIplain mHAI - 4.11 (- 7.21; - 1.01) 0.072 0.010
mHAI A - 11.93 (- 21.24; - 2.62) 0.068 0.013
mHAI B 2.96 (- 7.87; 13.78) 0.003 0.589
mHAI C - 6.56 (- 13.73; 0.60) 0.036 0.072
mHAI D - 7.94 (- 15.05; - 0.83) 0.052 0.029
RE: relative enhancement as a function of SI-based indices of the hepatic parenchyma. SI: hepatic signal
enhancement in plain or hepatobiliary (HBP) phase. mHAI: modified histologic activity index, based on findings of
inflammation according to Ishak [14]: mHAI A: Analysis of periportal or periseptal interface hepatitis (piecemeal
necrosis); mHAI C: Analysis of focal (spotty) lytic necrosis, apoptosis, and focal inflammation; mHAI D: Analysis of
portal inflammation. r2: coefficient of determination. p-value: level of significance.
https://doi.org/10.1371/journal.pone.0215752.t006
Table 7. Multiple linear regression analysis with the relative signal change (RE) as a dependent variable. The
model showed a coefficient of determination (R2) of 0.815.
Independent variable B (95% CI) p-value
Ishak-Score - 0.13 (- 0.15; - 0.12) < 0.001
modified HAI - 0.03 (- 0.04; - 0.01) 0.001
https://doi.org/10.1371/journal.pone.0215752.t007
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Discussion
Inflammation and fibrosis are strongly associated: hepatic inflammation initiates fibrogenesis
and maintains itself by promoting proinflammatory signaling molecule release and can occur
at any stage of liver fibrosis/cirrhosis [1, 2]. To be able to initiate an adequate treatment as
early as possible, researchers aim to distinguish inflammation and fibrosis in MR imaging
approaches. Variable MR techniques were applied to evaluate the fibrotic and inflammation
status of hepatic parenchyma [15]. Based on liver stiffness and damping ratio, assumptions of
the NAFLD status and the distinction to initial liver fibrosis have been shown [16, 17]. Simi-
larly, liver kinetics assessed in contrast-enhanced MR imaging as well as the apparent diffusion
coefficient can indicate liver fibrosis and inflammation [18–22].
Table 8. Enhancement values for patients with known parenchymal and tumor diseases and their corresponding mHAI (Modified histologic activity index) and
Ishak-Scores.
modified HAI Ishak-Score SI (plain) SI (HBP) RE
unknown/non-parenchymal disease 1.27 ± 1.44 1.27 ± 1.28 188.45 ± 36.28 363.65 ± 91.88 0.92 ± 0.24
Inflammatory disease 2.79 ±
2.27
3.85 ± 2.31 169.53 ± 28.11 261.71 ± 75.96 0.54 ± 0.35
Virus hepatitis 3.30 ± 2.41 4.25 ± 1.97 169.51 ± 27.25 254.52 ± 64.32 0.50 ± 0.28
Biliary disease 2.00 ± 2.24 2.56 ± 2.65 171.20 ± 22.41 290.41 ± 92.95 0.69 ± 0.48
Autoimmune hepatitis 2 6 195.17 244.00 0.25
Nonalcoholic steatosis hepatis 2.00 ± 1.00 4.33 ± 2.89 156.08 ± 54.46 229.43 ± 111.85 0.42 ± 0.29
Non-inflammatory disease 2.92 ± 2.24 3.08 ± 1.98 177.66 ± 29.57 295.47 ± 62.17 0.67 ±0.30
Alcoholic liver disease 3.12 ± 1.97 3.53 ± 2.00 185.20 ± 29.49 298.03 ± 63.56 0.61 ± 0.24
Nonalcoholic fatty liver disease 1.57 ± 1.13 1.86 ± 1.57 165.41 ± 23.28 306.33 ± 46.30 0.88 ± 0.35
Cardiac cirrhosis 9 4 135.23 175.80 0.30
non-tumorous disease 3.06 ± 2.18 4.13 ± 2.08 172.80 ± 32.41 259.67 ± 81.01 0.49 ± 0.32
malignant tumorous disease 2.04 ± 2.01 2.17 ± 1.86 179.31 ± 30.51 323.64 ± 78.61 0.80 ± 0.27
Hepatocellular carcinoma 2.42 ± 1.77 3.29 ± 1.92 171.63 ± 30.17 284.46 ± 67.60 0.66 ± 0.26
Cholangiocellular carcinoma 1.70 ± 1.25 1.70 ± 1.70 187.50 ± 32.74 345.08 ± 32.74 0.84 ± 0.25
liver metastasis 1.75 ± 2.53 1.05 ± 0.89 184.43 ± 29.14 359.93 ± 71.12 0.95 ± 0.20
Benign tumorous disease 0.33 ± 0.82 0.17 ± 0.41 202.58 ± 42.38 416.18 ± 93.96 1.07 ± 0.32
The data are presented as mean ± standard deviation (SD). Sum of all criteria-points represents the modified HAI. RE: relative enhancement as a function of SI-based
indices of the hepatic parenchyma. SI: hepatic signal enhancement in plain or hepatobiliary (HBP) phase.
https://doi.org/10.1371/journal.pone.0215752.t008






























Fig 5. Relative enhancement (RE) values plotted against the combined model for patients with unknown/non-parenchymal disease (A), known inflammatory- (B), and
non-inflammatory-parenchymal diseases (C). Each dot represents the median of the combined model. The corresponding correlations with RE as the dependent
variable are as followed: A, R2 = 0.503; B, R2 = 0.849: C, R2 = 0.812.
https://doi.org/10.1371/journal.pone.0215752.g005
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In this study, we analyzed histopathological hepatic inflammation and fibrosis parameters
in comparison to signal intensity indices on contrast-enhanced MRI, to analyze the influence
of hepatic inflammation on Gd-EOB-DTPA uptake into the liver parenchyma.
Similar to various studies [12, 23–25], we revealed the level of fibrosis as a strong predictor
of signal intensity-based indices (p< 0.001). Gd-EOB-DTPA is a hepatocyte-specific MR con-
trast agent having OATP1-mediated uptake and MRP2-mediated biliary excretion [26]. Hepa-
tobiliary MR contrast agents can be used to characterize the functional properties of the liver
parenchyma, and RE might be a reflection of the dysfunction of hepatocytes as a result of the
accumulation of liver fibrosis and increased necro inflammatory activity [27].
The development of liver cirrhosis is characterized by destructed lobular and vascular archi-
tecture which may promote nodular regeneration of liver tissue. In histological analysis, fibro-
sis is characterized by an accumulation of extracellular collagen fibers, proteoglycans, and
other macromolecules [13]. Since the hepatic uptake of Gd-EOB-DTPA depends on the integ-
rity of the hepatocyte mass, a reduced signal intensity during the HBP and relative enhance-
ment can be assumed. In plain SI-images there is currently a controversy discussion about the
influence of liver fibrosis/cirrhosis. Studies showed that the plain SI could be increased due to
tissue remodeling in liver fibrosis with inflammation and resulting edema [28–30], as well as
reduced based on increased deposition of paramagnetic macromolecules such as collagen tis-
sue with a lower water content [31, 32]. In this study, patients showed rather low levels of
inflammation (Fig 3), so one can assume that the influence of fibrotic/cirrhotic tissue remodel-
ing is more dominant than changes during hepatic inflammation.
Nevertheless, significant correlations between hepatic enhancement and signal intensity-
based indices could be found. Only a few studies analyzed hepatic inflammation in compari-
son to contrast-enhanced MRI: Yamada et al. [18] and Tsuda et al. [20] tested in animal studies
the effect of NASH caused inflammation on dynamic MR liver kinetics. They observed a sig-
nificant correlation of the parameters of Gd-EOB-DTPA kinetics (Tmax, T1/2) with steatosis
and inflammation [18] and distinct values of time to maximum RE for NASH with grade 2
necroinflammatory activity and control liver (p< 0.01) [20]. A study by Wu et al. [33] revealed
a significant difference between NASH and simple steatosis (p = 0.03), a negative correlation
of fibrosis stage and RE (r = - 0.469, p = 0.018) and no significant correlation between RE and
necroinflammatory grade (p = 0.09). In accordance with the observations of Wu et al., we
found a significant correlation between RE and the fibrosis stage (p< 0.001). However,
whereas Wu et al. could not find a correlation between the inflammation and RE, we found a
significant correlation between inflammation and RE (p =< 0.001). Our study protocol
diverged from Wu et al., as we used the scoring system according to Ishak [13, 14], a more
detailed scoring system not only for liver fibrosis but also for hepatic inflammation, while Wu
Fig 6. Relative enhancement (RE) values plotted against the combined model for patients with non-tumorous (A), benign tumorous (B), and malignant tumorous
diseases (C). Each dot represents the median of the combined model. The corresponding correlations with RE as the dependent variable are as followed: A, R2 = 0.852;
B, no significant correlation: C, R2 = 0.751. mHAI, histologic activity index.
https://doi.org/10.1371/journal.pone.0215752.g006
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et al. interpreted their samples by the Brunt classification, a grading system in the case of non-
alcoholic steatohepatitis [34]. In addition, Wu et al. investigated the effects of hepatic inflam-
mation in fatty liver diseases, whereas we studied a mixed population regarding the influence
of hepatic inflammation on contrast enhancement.
In the development of inflammation and fibrosis, various factors such as oxidative stress,
mitochondrial changes and hormonal disorders are considered as determinants [35–37].
Inflammation plays an important role in the remodeling of liver parenchyma [28–30]. In
response to damaged hepatocytes, apoptotic bodies are recruited to interact with dormant
hepatic stellate cells and Kupffer cells to activate and promote inflammatory and fibrogenic
reactions [38, 39]. Consequently, the enhanced inflammatory and immune-mediated
responses will promote hepatocyte necrosis and apoptosis, which promotes further fibrogenic
processes [40]. The subgroup analysis of the mHAI criteria revealed that the status of portal
inflammation (mHAI D) and periportal or periseptal interface hepatitis (piecemeal necrosis)
(mHAI A) are significant predictors (p� 0.001) of RE and the signal intensity of the HBP and
the plain images, while focal (spotty) lytic necrosis, apoptosis and focal inflammation (mHAI
C) showed a significant correlation with the HBP. As loss and degeneration of hepatocytes
characterize piecemeal necrosis at the lobular-portal interface [41], affected hepatocytes will
have decreased capacities of gadolinium-chelate-uptake and might show decrease hepatocyte
enhancement. Another characteristic of inflammation are lymphocytes which spill into the
hepatic parenchyma and the expansion of the extracellular space in the tissue due to increased
extracellular fluid accumulation (edema) [42, 43], and thus not only influencing the contrast
enhanced images but also the plain images.
Our study has several limitations. Hepatic enhancement analysis was performed with the
mean of several distinct ROI measurements to diminish the influence of heterogeneous dis-
tributed parenchymal changes. In contrast to this, histopathological samples were received
from distinct areas which might not represent hepatic status as accurate as desired. This might
also explain the fact that there is a difference regarding the tissue sample. Discrepancies in the
evaluation might be possible especially for the subgroup analysis concerning the mHAI crite-
ria. The results of our study support Feier et al.’s statement that strict criteria must be applied
to liver biopsy samples when used as reference procedures [44].
In addition, it must be stressed that we analyzed a mixed patient cohort, as it is typical in
clinical routine. A homogeneous cohort would be theoretically preferable and more suitable to
investigate the different aspects of inflammation. In subgroup analysis (Table 8, Figs 5 and 6)
we investigated the influence of hepatic inflammation on parenchymal enhancement for
patients with known parenchymal and tumor diseases. This subgroup analysis revealed that
the information about hepatic inflammation contributes to the variance elucidation especially
in patients with known inflammatory liver parenchymal diseases (R2 = 0.849) and non- tumor-
ous diseases (R2 = 0.852). Further, prospective studies are needed to investigate heterogeneous
etiologies of liver injury, in a retrospective study with only one center, it was difficult to avoid
bias in the sampling.
In general, fibrosis and inflammation are complex processes, which are influenced and
characterized by several different factors. This study underlines that not only the change in
liver architecture associated with hepatic fibrosis / cirrhosis affects uptake, but also other pro-
cesses such as increased deposition of hepatic water content, hypercellularity and an increased
amount of free bound water in the hepatic parenchyma often associated with inflammation of
the liver, affect the accumulation of hepatobiliary MR contrast agents such as Gd-EOB-DTPA.
Therefore, evaluation and grading based on a single aspect might be insufficient. Due to histo-
logical changes which occur in the process of inflammation, an effect on hepatocyte function-
ality and ability in gadolinium-chelate uptake was expected and could be shown in our study.
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In conclusion, the level of inflammation and the degree of fibrosis affect the hepatic enhance-
ment indices signal intensity and relative enhancement.
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